GlassScriptPhysician profile
Douglas M Mulinix
NPI 1346284973
$23,115.34
in general payments reported to CMS, 2019-2025
41 companies · $2,918 in 2025
The $2,918 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,527 · 2020: $2,393 · 2021: $7,923 · 2022: $2,957 · 2023: $2,916 · 2024: $1,481 · 2025: $2,918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,254 · Education: $61.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,253.93 |
| Education | $61.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,547.25 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,561.84 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,514.97 | 2019-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Neos Therapeutics, LP | $1,313.03 | 2019-2025 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $1,265.94 | 2019-2023 | Aplenzin, Wellbutrin |
| Tris Pharma INC | $1,154.15 | 2019-2024 | Dyanavel Xr |
| Lundbeck LLC | $1,134.12 | 2019-2025 | Rexulti, Abilify Maintena |
| Allergan, INC. | $971.44 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $916.01 | 2019-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $901.38 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $833.18 | 2019-2024 | Jornay Pm |
| Corium, LLC | $810.94 | 2021-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $632.20 | 2019-2024 | Trintellix |
| Axsome Therapeutics, INC. | $529.06 | 2022-2025 | Auvelity, Sunosi |
| Eisai INC. | $522.55 | 2020-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $496.84 | 2019-2025 | Spravato |
| Avanir Pharmaceuticals, INC. | $436.04 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $298.64 | 2020-2025 | Ingrezza |
| Alkermes, INC. | $284.49 | 2021-2024 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $275.15 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| E.R. Squibb & Sons, L.L.C. | $243.70 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $230.40 | 2025 | Jornay Pm |
| Rhodes Pharmaceuticals L.P. | $172.12 | 2019 | |
| Noven Therapeutics, LLC | $150.61 | 2023-2025 | Xelstrym, Secuado |
| Jazz Pharmaceuticals INC. | $122.70 | 2019-2021 | |
| Shire North American Group INC | $119.65 | 2019 | |
| Orexo US, INC. | $107.13 | 2019-2023 | Zubsolv |
| Vertical Pharmaceuticals, LLC | $85.67 | 2019-2024 | Methylphenidate Hydrochloride |
| Idorsia Pharmaceuticals US INC | $82.73 | 2023 | Quviviq |
| Harmony Biosciences LLC | $77.45 | 2024-2025 | |
| Adlon Therapeutics L.P. | $50.31 | 2020-2021 | |
| Indivior INC. | $48.91 | 2019-2025 | Sublocade |
| Aytu Biopharma, INC. | $40.16 | 2021 | |
| Braeburn INC. | $34.45 | 2025 | Brixadi |
| Novo Nordisk INC | $33.07 | 2022-2023 | Wegovy |
| Owp Pharmaceuticals, INC. | $26.57 | 2019 | |
| Alfasigma USA, INC. | $26.17 | 2021 | |
| Biogen, INC. | $24.97 | 2025 | Zurzuvae |
| Neuronetics, INC. | $17.38 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.13 | 2020 | |
| Merck Sharp & Dohme LLC | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Mulinix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.